{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-23-000049","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2023-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.091904+00:00","generated_at":"2026-06-12T22:21:51.500272+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biohaven Q2 net loss $90.3M; cash $349M; FDA refuses SCA3 NDA; pipeline advances","bullets":["Net loss $90.3M ($1.32/sh) vs $203.3M ($5.16/sh) in Q2 2022; adjusted net loss $85.7M ($1.25/sh).","Cash and marketable securities $349.0M as of June 30, 2023, down from $467.9M at Dec 31, 2022.","BHV-7000 Kv7 activator showed CNS target engagement without somnolence; Phase 2/3 in epilepsy and bipolar disorder planned 2H 2023.","FDA refused to file troriluzole NDA for SCA3; Biohaven plans Type A meeting to address FDA concerns.","BHV-8000 (TYK2/JAK1) Phase 1 SAD dosed, well tolerated; Phase 2 in Parkinson's disease planned 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-23-000049","json":"https://secwatch.observer/filing/0001935979-23-000049.json","markdown":"https://secwatch.observer/filing/0001935979-23-000049.md","text":"https://secwatch.observer/filing/0001935979-23-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000049/0001935979-23-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000049/bhvn-20230731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T22:21:51.500272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8eb587ac255f95f6158f77110bcb618701ff63ac","claim":"Biohaven Ltd. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000049/0001935979-23-000049-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}